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ABSTRACT
Objectives: To determine the efficacy of adding abacavir (Ziagen, ABC) to optimal stable
background antiretroviral therapy (SBG) to AIDS dementia complex (ADC) patients and address
trial design.
Design: Phase III randomized, double-blind placebo-controlled trial.
Setting: Tertiary outpatient clinics.
Participants: ADC patients on SBG for  8 wk.
Interventions: Participants were randomized to ABC or matched placebo for 12 wk.
Outcome Measures: The primary outcome measure was the change in the summary
neuropsychological Z score (NPZ). Secondary measures were HIV RNA and the immune
activation markers b-2 microglobulin, soluble tumor necrosis factor (TNF) receptor 2, and
quinolinic acid.
Results: 105 participants were enrolled. The median change in NPZ at week 12 wasþ0.76 for
the ABC þ SBG and þ0.63 for the SBG groups (p ¼ 0.735). The lack of efficacy was unlikely
related to possible limited antiviral efficacy of ABC: at week 12 more ABC than placebo
participants had plasma HIV RNA  400 copies/mL (p ¼ 0.002). There were, however, other
factors. Two thirds of patients were subsequently found to have had baseline resistance to ABC.
Second, there was an unanticipated beneficial effect of SBG that extended beyond 8 wk to 5
mo, thereby rendering some of the patients at baseline unstable. Third, there was an
unexpectedly large variability in neuropsychological performance that underpowered the
study. Fourth, there was a relative lack of activity of ADC: 56% of all patients had baseline
cerebrospinal fluid (CSF) HIV-1 RNA ,100 copies/mL and 83% had CSF b-2 microglobulin ,3
nmol/L at baseline.
Conclusions: The addition of ABC to SBG for ADC patients was not efficacious, possibly
because of the inefficacy of ABC per se, baseline drug resistance, prolonged benefit from
existing therapy, difficulties with sample size calculations, and lack of disease activity.
Assessment of these trial design factors is critical in the design of future ADC trials.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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AIDS dementia complex (ADC) is a relatively common
complication of advanced HIV disease, occurring in approx-
imately 20% of patients in the era before highly active
antiretroviral therapy (HAART) [1]. ADC is characterized by a
complex of cognitive, motor, and behavioral abnormalities
[2]. While the incidence in the HAART era has halved relative
to pre-HAART, the prevalence has approximately doubled,
because of the life-extending effect of HAART [3]. Zidovu-
dine (ZDV) is the only antiretroviral drug whose efﬁcacy in
ADC is supported by the results of a randomized, placebo-
controlled trial [4]. In addition, the efﬁcacy of ZDV is
supported by anecdotal and observational studies [5,6], as
well as evidence of signiﬁcant declines in the concentrations
of cerebrospinal ﬂuid (CSF) immune activation markers such
as b-2 microglobulin and quinolinic acid, both of which are
closely correlated with the severity of ADC and its response to
therapy [7,8]. A number of antiretroviral drugs may be
effective in the treatment of ADC, based upon reduction of
HIV-1 RNA in the CSF, as seen with stavudine (d4T),
lamivudine (3TC) [9], and indinavir [10]; the measurement
of potentially efﬁcacious drug concentrations in the CSF, as
observed with nevirapine and efavirenz [11,12]; and efﬁcacy
in in vitro models (d4T, 3TC, and efavirenz) [13]. Although
the effect of combining these and other antiretroviral drugs
within HAART on clinical and neuropsychological perform-
ance has not been systematically studied, there is increasing
evidence suggesting a beneﬁcial impact on ADC [14–17].
For an antiretroviral therapy (ART) to be effective in ADC,
theoretically it should have potent antiviral activity, ability to
penetrate the brain at efﬁcacious concentrations, and activity
in macrophages and microglia, the primary targets of HIV
infection within the brain. While the need for adequate brain
penetration is controversial, studies addressing this issue thus
far have been incomplete. There has been variability in the
number of drugs that have been assessed in the regimen (at
times one drug and at other times three), in the compre-
hensiveness of neuropsychological assessments, in the level of
impairment of the patients, and in the potential for drug
interactions. Moreover, there has been no head-to-head
comparison of a brain-penetrating three-drug regimen versus
one that is not penetrating. In a recent study, we have found
that while overall there does not appear to be any beneﬁt from
a brain-penetrating regimen in neurologically asymptomatic
patients, there is neuropsychological beneﬁt in a subset of
patients with signiﬁcant dysfunction [18].
Abacavir (Ziagen, ABC) is metabolized to a novel 29
deoxyguanosine analog nucleoside reverse transcriptase
inhibitor (NRTI) that fulﬁls these criteria. The compound
has potent antiviral efﬁcacy, can cross the blood brain barrier
to an extent similar to ZDV, and has good antiviral activity in
macrophages in vitro [19] and microglia [20]. Furthermore,
while ZDV is active against de novo infection of macrophages,
but not against chronic infection in resting monocyte lineage
cells, ABC is active against both [21]. Consequently, a
controlled study was conducted to determine the efﬁcacy of
ABC as part of combination therapy in ADC. An ABC dose of
600 mg twice a day (double the standard dose) was selected in
an attempt to maximize the central nervous system ABC
concentrations while providing an acceptable level of safety
[22]. Results for the 12-wk randomized phase of the study,
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Editorial Commentary
Background: AIDS dementia complex (ADC) was first identified early in
the HIV epidemic and at that time affected a substantial proportion of
patients with AIDS. Patients with ADC experience dementia as well as
disordered behavior and problems with movement and balance. ADC is
now much less common in locations where patients have access to
HAART (highly active antiretroviral therapy), consisting of combinations
of several drugs that attack the virus at different stages of its life cycle. At
present, however, there are no generally accepted guidelines for the best
treatment of people with ADC. It has been thought for some time that
the best treatment regimens for people with ADC would include drugs
that cross the barrier between blood and brain well. Shortly following
the introduction of HAART, a trial was carried out to find out whether
adding one particular drug, abacavir, to existing combinations of drugs
would be beneficial in people with ADC. This drug is known to cross the
barrier between the blood and brain. The trial enrolled HIV-positive
individuals with mild to moderate ADC and who were already receiving
antiretroviral drug treatment. 105 participants were assigned at random
to receive either high-dose abacavir or a placebo, in addition to their
existing therapy. The primary outcome of the trial was a summary of
performance on a set of different tests, designed to evaluate cognitive,
behavior, and movement skills, at 12 weeks. Other outcomes included
levels of HIV RNA (viral load) in fluid around the brain, as well as other
neurological evaluations, and the level of HIV RNA and CD4
þ T cells (the
cells infected by HIV) in blood.
What this trial shows: When comparing the change in performance
scores for individuals randomized to either abacavir or placebo, the
results showed an improvement in scores for both groups, but no
significant difference in improvement between the two groups. Similarly,
the levels of HIV RNA in the cerebrospinal fluid did not differ between
the two groups being compared, and other neurological tests did not
show any differences between the two groups. However, at 12 weeks,
patients receiving abacavir were more likely to have low levels of HIV
RNA in their blood, suggesting that abacavir was active against the virus,
but this did not translate into an additional improvement of these
patients’ dementia. The overall rates of adverse events were roughly
comparable between the two groups in the trial, although participants
receiving abacavir were more likely to experience certain types of events,
such as nausea.
Strengths and limitations: The trial was appropriately randomized and
controlled, using central telephone procedures for randomizing partic-
ipants and subsequent blinding of patients and trial investigators. These
procedures help minimize the chance of bias in assigning participants to
the different arms as well as in the subsequent performance of
individuals within the trial and the assessment of their outcomes.
Limitations in the study design have been identified. One limitation is
that individuals enrolled into the trial may not in fact have been
receiving their existing HAART regimen for long enough to experience its
optimal effect, and therefore the improvement seen in both groups
could have resulted from an ongoing response to their existing regimen.
It is also possible that patients improved in their test scores over the
course of the trial simply because they became more familiar with the
tests and not because their condition improved. This is a problem in all
such trials that try to improve mental function. Finally, a limitation may
have been the inclusion of patients who did not have active disease
leading to worsening dementia.
Contribution to the evidence: The findings from this trial suggest that
adding high-dose abacavir to existing HAART is not beneficial for
patients with ADC. However, the trial provides several insights into the
way that future studies of this type can be done, and which typically
pose a number of challenging design problems. In particular, sensitive
markers are needed that will allow researchers to monitor progression of
ADC and patients’ response to therapy.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.presented below, did not show any beneﬁt for the addition of
ABC. The trial details are analyzed here to determine the
reasons for this lack of efﬁcacy.
METHODS
Participants
Thirteen sites in Australia, Canada, the United Kingdom, and
the United States participated. Each site was a tertiary
referral outpatient clinic. Conﬁrmed HIV-1 seropositive male
or female participants, aged 18 to 65 y, diagnosed with Stage 1
or 2 (mild to moderate) ADC [23] and stable on optimal ART
(SBG) for a minimum of 8 wk prior to study were enrolled.
Participants had to be impaired by at least 1.5 standard
deviations (SDs) below normal in at least two neuropsycho-
logical domains from the chosen test battery (see below).
Participants with evidence of confounding neurological
disease or presenting with other central nervous system
opportunistic infections or neoplasms were excluded. No
restriction on previous ART was imposed.
Interventions
This was a phase III randomized, placebo-controlled, double-
blind study. Ethics approval was obtained from each site.
Informed consent was obtained from each participant or
from their legal guardian. All clinical investigations were
conducted according to the principles expressed in the
Declaration of Helsinki.
Participants received 600 mg of ABC or matched placebo
twice a day in addition to their current SBG for the 12 wk of
the study; changes in drugs or drug dosages within the SBG
were not permitted during this time. Participants who
experienced progression or severe antiretroviral drug tox-
icity not related to ABC during the study could receive open
label ABC, 600 mg twice a day, and change the SBG as
appropriate if a minimum of 6 wk on study had been
completed. Participants were deﬁned as having clinically
progressed if their ADC clinical status deteriorated by at least
one stage [23] with this endpoint validated by a core
committee.
Objectives
The objective of the trial was to determine the efﬁcacy of
adding ABC to SBG to patients with ADC.
Outcome Measures
T h ep r i m a r yo u t c o m em e a s u r ew a st h ec h a n g ei nt h e
summary neuropsychological Z score (NPZ). Secondary
measures were CSF HIV RNA and the immune activation
markers b-2 microglobulin and soluble tumor necrosis factor
(TNF) receptor 2 and quinolinic acid. Ancillary measures
were semi-quantitative neurological evaluations, plasma HIV
RNA, CD4
þ cell count, mutations in the reverse transcriptase
(RT) gene, and pharmacokinetic analyses.
Neuropsychological performance. Neuropsychological per-
formance was measured by a test battery comprised of the
Rey Auditory Verbal Learning Test (RAVLT) Trials I–V (total
words across ﬁve trials); Delayed Recall, Grooved Pegboard
(dominant and nondominant hand); Trail Making B, Symbol
Digit, Cal Cap Reaction Time (choice and sequential RT); and
Verbal Fluency (word generation on FAS test). These tests are
widely used in the United States, the United Kingdom, and
Australia and have been validated in these populations. Z
scores were constructed using the Multicentre-AIDS Cohort
Study (MACS) reference data corrected for age and education
[24].
CSF HIV-1 RNA. Collection of CSF samples was compul-
sory at day 7, but voluntary at weeks 6 and 12. CSF HIV-1
RNA was stored with appropriate precautions at  70 8C and
later batch-extracted, ampliﬁed, hybridized, and detected
using NASBA HIV-1 QT technology (Organon Teknika) with
a detection limit of 100 copies/mL.
CSF markers of immune activation. b-2 microglobulin and
soluble TNF receptor 2 (sTNF-R2) [25] were measured using
commercially available kits. Quinolinic acid was measured
using gas chromatography/mass spectrometry.
Other Measures
Neurological evaluation. Neurological evaluations were
performed using the AIDS Clinical Trials Group (ACTG)
assessments, pre-study (day 14), weeks 6 and 12. Cognitive
function, motor function, behavior/mood, mental status, level
of consciousness, adapted mini-mental status exam, response
slowing, cranial nerves, ocular motility, facial expression,
limb strength, coordination, reﬂexes, and neuropathy were
examined. The total neurological subscore was calculated
(from a previously validated formula [B. J. Brew and R. W.
Price, personal communication] that gave certain weightings
to the latter aspects of the neurological evaluation) and used
as an objective tool to conﬁrm the participants’ ADC stage
(see Text S1). The neurological subscores were as follows:
ADC Stage 1 (4–6), Stage 2 (7–9), and Stage 3 (10–12).
Neuropathy was deﬁned as the presence of symptoms of
numbness and/or pain in the feet with absent or depressed
ankle reﬂexes and diminished perception of pain, temper-
ature, and vibration in the feet.
Plasma HIV-1 RNA. Plasma HIV-1 RNA was assessed pre-
study (day 7), at weeks 2, 4, 6, 8, and 12. Quantitation of
plasma HIV-1 RNA was carried out using the RNA PCR
technique developed by Roche Molecular Systems (http://
www.roche-diagnostics.com) (Amplicor HIV-1 MONITOR
v1.0, detection limit 400 copies/mL).
CD4
þ cell count. CD4
þ cell count was assessed by ﬂow
cytometry at day 0, weeks 2, 4, 6, 8, and 12.
Mutations in the HIV-1 RT gene in plasma and CSF. The
HIV-1 coding region was ampliﬁed using the rTth XL RT-
PCR kit (Perkin-Elmer). Puriﬁed cDNA was sequenced using
the PRISM FS dye terminator cycle sequencing kit (Applied
Biosystems, http://www.appliedbiosystems.com) and resolved
on an ABI 373 DNA sequencer. Data were aligned and
analyzed using the Sequencher program. Where mixed viral
populations were present, a ratio of mutant to wild-type
electropherogram peak size greater than 70% was designated
as mutant.
Pharmacokinetic measures. Voluntary CSF samples (0.5
mL) were collected from a subset of participants at weeks 6
and 12 at various times after dosing. ABC concentrations
were determined by a validated analytical method. Results are
reported in four pre-deﬁned time intervals.
Safety and tolerability. Safety and tolerability were eval-
uated by assessing clinical adverse events and clinical
laboratory values. Adverse events and toxicities were graded
using the ACTG grading scale.
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We calculated a priori that a sample size of 45 participants
per treatment group would be required to provide 90%
power to detect a difference between treatment groups of 0.6
in the change from baseline of summary NPZ at week 12. This
sample size assumes a¼0.05, SD¼0.75, and a dropout rate of
20%–25%.
Randomization
Randomization was stratiﬁed by ZDV use (use versus nonuse)
as part of their SBG to determine if there was any synergy
between ZDV and ABC: stratum A if their existing SBG
contained ZDV or stratum B if it did not. There were no
limits on sample size within each stratum. Participants were
then centrally randomized by ClinPhone at GlaxoSmithKline.
The randomization schedule was loaded into the IVRS at
ClinPhone and subsequently administered by them. The
randomization schedule remained blinded until the database
authorization was complete and after the data had been
collected and cleaned. The patient, the investigator, the
assessor, and GlaxoSmithKline were all blind to the treatment
status of each patient. The ABC and placebo tablets were
identical in appearance and taste. No steps, however, were
undertaken to check the success of the blinding.
Statistical Methods
All efﬁcacy analyses were performed on the Intent-to-Treat
(ITT) population, deﬁned as all participants with data who
were enrolled in the 12-wk phase of the study as randomized,
regardless of actual treatment and the eventual outcome of
study participation. Missing data were dealt with by carrying
the last observation forward.
The NPZ was calculated as the actual test result minus the
reference group mean divided by reference group SD. A
summary NPZ was computed as the mean of the eight
individual NPZ. Treatment groups were compared using the
stratiﬁed Wilcoxon rank sum test on the change from
baseline to week 12 in the summary NPZ. Study termination
at week 12 was chosen on the basis of the previously
mentioned randomized placebo controlled trial of ZDV in
ADC [4].
Several retrospective exploratory sub-analyses were tar-
geted at treatment effect within each of the three neuro-
psychological domains, effect of impairment at baseline on
neuropsychological outcome and impact of background
therapy. In addition to NPZ analyses, neuropsychological
performance data were also examined using NP deﬁcit score
analysis as described by Heaton et al. [26]. The results from
NP deﬁcit score analysis did not differ from NPZ summary
score method and only the results of the NPZ summary score
will be presented.
RESULTS
Participant Flow
A total of 105 participants were randomized: 52 to the ABCþ
SBG group and 53 to the SBG alone group. Three
participants from each group withdrew from the study prior
to baseline evaluation for personal reasons. There were three
protocol violations: two participants with ADC Stage 3 and
one with ADC Stage 0.5 were entered into the trial and
allowed to complete the study. Of the 99 participants from
whom data were collected, 42 (86%) in the ABCþSBG group
and 41 (82%) in the SBG group completed the 12-wk
randomized phase (Figure 1). Seven participants from the
ABC þ SBG group discontinued randomized therapy pre-
maturely; three participants discontinued study drug due to
adverse events (one of which proved fatal), two participants
experienced clinical deterioration, and two participants
withdrew consent. Nine participants from the SBG group
discontinued randomized therapy prematurely; four partic-
ipants discontinued study drug due to adverse events (one of
which proved fatal), two participants experienced clinical
deterioration, one participant was lost to follow-up, one
participant was a protocol violation, and one participant
withdrew consent. The trial commenced on September 4,
1996 and ended January 8, 1998.
Baseline Data
Table 1 shows the baseline characteristics of the two groups,
baseline measures and treatment group. The median plasma
HIV-1 RNA was the only variable statistically signiﬁcantly
different between the groups. Only two participants were
female despite there being no restrictions to entering
females. All participants, except one, were receiving treat-
ment with between one and ﬁve ARTs at study entry;
approximately half were receiving triple ART. The distribu-
tion of nucleoside reverse transcriptase inhibitors (NRTIs),
non-nucleoside reverse transcriptase inhibitors, and protease
inhibitors (PIs) was fairly even between the groups. The most
commonly administered PI was indinavir (37% of the ABC þ
SBG group and 40% of the SBG alone group).
Primary Outcomes
Neuropsychological performance. Table 2 shows the im-
provement in both groups without any additional beneﬁt
from ABC by intention to treat analysis (p ¼ 0.735).
Secondary Outcomes
CSF HIV-1 RNA. The baseline HIV-1 RNA levels in CSF,
measured in a subset of 79 participants, were similar between
treatment groups; 25/45 (56%) of participants from the ABC
þSBG group and 19/34 (56%) from the SBG alone group had
HIV-1 RNA levels of  100 copies/mL. At week 12, the
majority of available CSF samples had HIV-1 RNA levels
below the limit of detection; 19/23 (83%) of participants from
the ABC þ SBG group and 12/16 (75%) of participants from
the SBG alone group had CSF HIV-1 RNA  100 copies/mL. If
the median reductions in CSF HIV-1 RNA from baseline are
estimated using week 12 data (or using week 6 data if week 12
value is missing), the median HIV-1 RNA reduction for the
ABC þ SBG group of  0.64 log10 copies/mL (range  1.95 to
þ0.23, n ¼ 13) was slightly more favorable than that observed
for the SBG alone group of  0.26 log10 copies/mL (range
 3.46 to þ0.67, n ¼ 8) but still not statistically signiﬁcant.
There was no statistically signiﬁcant correlation between
change in CSF HIV-1 RNA and changes in either NPZ or
plasma HIV-1 RNA.
CSF markers of immune activation. Changes in sTNF-R2,
quinolinic acid, and b-2 microglobulin levels from baseline
were compared with CSF HIV-1 RNA changes by treatment
group. There were decreases in sTNF-R2 from baseline of 30
pg/mL (n¼7) for the ABCþSBG group and 88 pg/mL (n ¼6)
for the SBG alone group, and a decrease from baseline in
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Abacavir in AIDS Dementia Complexquinolinic acid of 80 lg/mL (n ¼8) for the ABCþSBG group
and 186 lg/mL (n ¼ 6) for the SBG group, but no signiﬁcant
associations with CSF HIV-1 RNA changes were identiﬁed. At
baseline, 12/16 (75%) of participants from the SBG alone
group and 22/25 (88%) of participants from the ABC þ SBG
group had CSF b-2 microglobulin levels ,3.0 nmoles/mL; by
week 12 decreases of 0.10 nmoles/mL (n¼7) in the ABCþSBG
group and 0.12 nmoles/mL (n ¼ 5) in the SBG group were
observed. None of these changes in CSF markers reached
statistical signiﬁcance, even when the analyses were repeated
as a percent change from baseline.
Ancillary Analyses
Neurological evaluations. There was improvement in the
neurological subscore in both groups at week 6 to 5 and at
week 12 to 4. There was no difference in the ADC stages at
week 12 between the groups. Only two participants, both in
the SBG group, demonstrated progression of ADC stage.
There was no difference in neuropathy between the groups.
Plasma HIV-1 RNA. Median change in plasma HIV-1 RNA
from baseline showed no sustained response in either
treatment group. In contrast, the percentage of participants
with plasma HIV-1 RNA  400 copies/mL was statistically
signiﬁcant at week 12 (p ¼ 0.002) in favor of ABC (Figure 2).
By week 12, approximately 4-fold more participants in the
ABC þ SBG group had plasma HIV-1 RNA  400 copies/mL
when compared to the SBG group: 5/39 (46%, ABC þ SBG
group) versus 17/37 (13%, SBG group). However, the groups
were not balanced with respect to median plasma HIV-1 RNA
at baseline, hence an additional analysis was conducted that
examined changes in baseline detectability status at weeks 4
and 12. Participants were classiﬁed as improved (detectable at
baseline but became undetectable at a later time point),
worsened (undetectable at baseline and became detectable at
a later time point), or no change (remained detectable or
undetectable). Using this conservative analysis, which penal-
izes the ABCþSBG group for having a greater percentage of
patients with undetectable plasma HIV-1 RNA at baseline, the
Figure 1. The CONSORT Flowchart for the ABC ADC Trial
doi:10.1371/journal.pctr.0020013.g001
www.plosclinicaltrials.org March | 2007 | e13 0005
Abacavir in AIDS Dementia Complexresults still favored the ABC þ SBG group at week 12 (p ¼
0.029) (Figure 2).
Viral mutations in the RT gene in plasma and CSF. Due
primarily to low HIV-1 RNA copy number, only 67 baseline
plasma samples and 26 baseline CSF samples were successfully
genotyped. Approximately 90% (60/67) of participants for
whom baseline genotyping of plasma viral isolates was
successfully completed had evidence of mutations in the
HIV-1 RT related to prior NRTI use, reﬂecting the extensive
prior treatment of these participants. A baseline M184V
plasma HIV-1 RT mutation was detected in 50/67 (75%) of
participants. Three or more mutations associated with NRTI
resistance at baseline were seen in 44/67 (66%) participants.
Despite this, 46% of participants in the ABC þ SBG group
and 13% in the SBG alone group had plasma HIV-1 RNA
 400 copies/mL at week 12.
CSF and plasma HIV-1 RT genotypes were discordant in
14/21 (67%) of baseline pairs. The majority of the differences
were minor changes in ZDV/d4T mutation proﬁles. At
baseline, one participant in the ABC þ SBG group and six
participants from the SBG alone group had the M184V
mutation in virus from plasma but not from CSF.
Correlations between CSF HIV-1 RNA response at week 12
and baseline CSF viral genotype were available for ﬁve
participants in the ABC þ SBG group and six participants in
the SBG alone group. In the ABC þ SBG group, 3/5 baseline
CSF isolates carried  3 NRTI-associated mutations and 2/3
had CSF HIV-1 RNA  100 copies/mL at week 12, and in the
SBG alone group 5/6 baseline CSF isolates carried  3 NRTI-
associated mutations and 3/5 had CSF HIV-1 RNA  100
copies/mL at week 12.
CD4þ cell count. There was no notable difference in
response between treatment groups with a median change
from baseline at week 12 of þ9 cells/mm
3 (range 194 to þ411
cells/mm
3) in the ABC þ SBG group and  1 cells/mm
3 (range
 162 to þ278 cells/mm
3) in the SBG alone group.
Pharmacokinetic measures. Thirty-ﬁve CSF pharmacoki-
netic samples were obtained from participants randomized to
receive ABC. The mean CSF ABC concentration increased
consistently between the ﬁrst and last collection intervals
(0.126 lg/mL from 0.5–1.0 h, 0.356 lg/mL from 1.0–2.0 h,
0.575 lg/ml from 2.0–3.0 h, and 0.741 lg/ml from 3.0–4.0 h).
While peak CSF concentrations may not have been attained
due to the limited collection period (4 h post-dose in a 12-h
dosing interval), the observed peak values are 9-fold greater
than a representative IC50 for ABC (0.08 lg/mL) [17].
Post hoc exploratory analyses. In order to further inves-
tigate why a difference between treatment groups was not
detected, additional analyses were conducted on completion
of the study. These focused on two hypotheses: (1) the
presence of a PI in the therapy inﬂuenced the result and (2)
the degree of neuropsychological impairment inﬂuenced the
trial result. Analyses of these hypotheses did not reach
statistical signiﬁcance though positive trends were evident in
.......................................................................................
Table 1. Baseline Measures
Parameters Treatment Group
ABC þ SBG
n ¼ 49
SBG
n ¼ 50
Median plasma HIV-1 RNA 3.7 4.5
Range (log10 copies/mL) (2.6–5.9) (2.6–6.1)
Number of participants with
plasma HIV RNA results
n ¼ 43
a n ¼ 45
Median CD4þ cell count 149.5 188
Range (cells/mm
3) (7–915) (5–801)
Number of participants with
CD4þ cell count result
n ¼ 45 n ¼ 49
Median baseline summary NPZ  2.3  1.8
Range ( 8t o0 ) (  8t o 1)
Number of participants with NPZ n ¼ 49 n ¼ 50
Memorial Sloan-Kettering rating
Subclinical (Stage 0.5) 1 (2%) 0
Mild (Stage 1) 28 (57%) 33 (66%)
Moderate (Stage 2) 19 (39%) 16 (32%)
Severe (Stage 3) 1 (2%) 1 (2%)
Number of participants with
Memorial Sloan-Kettering rating
n ¼ 49 n ¼ 50
Total median neurology subscore 6 6
Range
b (0–13) (1–11)
Number of participants with
neurology subscore
n ¼ 49 n ¼ 48
Median neuropathy final score 2 2
Range (0–8) (0–4)
Number of participants with
neuropathy final score
b
n ¼ 49 n ¼ 48
aNot all patients had baseline measures performed despite being randomized. The
numbers in parentheses refer to the numbers of patients that had the baseline
measure.
bSee Text S1 for scoring details.
doi:10.1371/journal.pctr.0020013.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 2. Summary Neuropsychological Z-Score Changes from Baseline: Intent-to-Treat
Week Parameters Total Stratum A (Current ZDV) Stratum B (No Current ZDV)
ABC þ SBG SBG ABC þ SBG ABC ABC þ SBG SBG
Week 6 Median 0.58 0.39 0.56 0.39 0.80 0.38
Number of participants n ¼ 46 n ¼ 48 n ¼ 25 n ¼ 26 n ¼ 21 n ¼ 22
(Min,max) ( 2.49,2.73) ( 5.10,2.76) ( 1.02,2.73) ( 5.10,2.76) ( 2.49,2.26) ( 2.54,2.28)
Mean 0.60 0.24 0.56 0.10 0.66 0.40
SE 0.14 0.20 0.17 0.31 0.23 0.25
Week 12 Median 0.76 0.63 0.44 0.55 1.34 0.77
Number of participants n ¼ 39 n ¼ 44 n ¼ 22 n ¼ 25 n ¼ 17 n ¼ 19
(Min,max) ( 2.53,2.69) ( 3.89,3.32) ( 2.53,2.41) ( 3.89,2.55) ( 1.17,2.69) ( 1.78,3.32)
Mean 0.72 0.59 0.47 0.38 1.06 0.86
SE 0.17 0.18 0.21 0.26 0.26 0.24
SE, standard error of the mean.
doi:10.1371/journal.pctr.0020013.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PIs and in those who were more severely neurologically
impaired (Table 3).
Adverse Events
In the ABC þ SBG and SBG alone groups, 96% (ABC þ SBG
group) and 92% (SBG group) of participants experienced an
adverse event during the randomized study period. The most
frequent drug-related adverse events were nausea (41% ABC
þSBG; 18% SBG alone), diarrhea (16% ABCþSBG; 8% SBG
alone), malaise and fatigue (16% ABC þ SBG; 12% SBG
alone), nausea and vomiting (10% ABC þ SBG; 4% SBG
alone), and headache (10% ABCþSBG; 18% SBG alone). The
incidences of these drug-related adverse events were not
signiﬁcantly different between treatment groups, with the
exception of nausea in the ABC þ SBG group (p ¼ 0.01).
Three participants in the ABC þ SBG group discontinued
treatment before week 12 due to an adverse event, one of
which was fatal: seizures followed by a cardiac arrest. The
fatality was not considered related to ABC as the patient was
a known epileptic, and there have been no reports of
exacerbation of epilepsy control since ABC has been
approved for use. One participant experienced an ABC-
related hypersensitivity reaction, which resolved on cessation
of ABC. Four participants in the SBG alone group experi-
enced adverse events, one of which was fatal, respiratory
arrest secondary to anemia. No notable trends were observed
in any of the safety parameters examined, including the
clinical laboratory values.
DISCUSSION
Interpretation
This 12-wk, randomized, placebo-controlled, double-blind
study did not show any additional beneﬁt from adding ABC
to SBG ART in this group of participants with ADC; indeed,
both treatment groups showed an improvement in neuro-
psychological performance during the 12 wk of study. Given
that approximately two thirds of the patients in the trial had
Stage 1 ADC and that Stage 1 overlaps with minor cognitive
motor disorder as deﬁned by the American Academy of
Neurology, it seems likely that these results also pertain to less
severe forms of HIV-related cognitive impairment. Analysis
of the data reveals important issues in ADC trial design and
patient management.
Generalizability
There are two general theoretical reasons for the lack of
additional demonstrable clinical activity: either ABC does not
have efﬁcacy or aspects of the trial design were ﬂawed.
The median CSF HIV-1 RNA was reduced, albeit by a
modest 0.64 log10 copies/mL over the 12 wk and ABC was
present in the CSF in potentially efﬁcacious concentrations,
on average 9-fold greater than the IC50 reported for ABC for
the wild-type virus. Moreover, there is published evidence for
the systemic and neurological efﬁcacy of ABC. This was
Figure 2. Antiviral Efficacy of ABC
The percentage of participants in the two arms of the trial (ABC arm is the further bar to the right at each time point) on the y-axis with undetectable plasma HIV
viral load at the beginning, week 4, and at the end of the trial (week 12).
doi:10.1371/journal.pctr.0020013.g002
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Table 3. Summary of Median Neuropsychological Z-scores:
Change from Baseline to Week 12 by Subgroup
Subgroup Treatment Group 95% CI
ABC þ SBG SBG
Protease inhibitors 0.6 (n ¼ 24) 0.7 (n ¼ 26) ( 0.48 to 0.39)
(Range) ( 0.6 to 2.7) ( 3.9 to 3.3)
No protease inhibitors 1.3 (n ¼ 15) 0.6 (n ¼ 18) ( 0.69 to 1.02)
(Range) ( 2.5 to 2.4) ( 2.1 to 2.6)
Baseline NPZ score:
 8t o 4
1.0 (n ¼ 9) 0.1 (n ¼ 6) ( 1.24 to 2.11)
Baseline NPZ score:
.  4t o 2
0.8 (n ¼ 12) 0.5 (n ¼ 14) ( 0.90 to 1.84)
Baseline NPZ score:
.  2t o0
0.4 (n ¼ 20) 0.7 (n ¼ 25) ( 0.63 to 0.17)
doi:10.1371/journal.pctr.0020013.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Lanier et al. have shown in a meta-analysis of ﬁve studies
where ABC was added to existing therapy that there was
signiﬁcant reduction in plasma HIV viral load even in
patients with baseline NRTI mutations as long as the number
of these did not exceed four [27]. The evidence for the
neurological efﬁcacy of ABC to date is more complex.
Limoges et al. [28] have shown that in the brains of SCID
mice with HIV encephalitis ABC decreased viral load by
approximately one log while the efﬁcacy of ZDV and d4T
were variable but in general inferior. Indeed, ABC was very
effective at limiting the spread of infection and microglial
nodule formation. On the other hand, Kandanearatchi et al.
[29] found that neither ABC nor ZDV made a signiﬁcant
difference to HIV replication in a human fetal brain
aggregate model and that only d4T was efﬁcacious when
given 24 h prior to HIV infection. These ﬁndings do not
accord with the known clinical efﬁcacy of ZDV and raise
potential concerns over the appropriateness of the model for
assessment of antiretroviral efﬁcacy. The only other study
that tried parenthetically to assess the neurological efﬁcacy of
ABC is that by McCoig et al. [30]. In a small substudy, 13
children were randomized to receive ABC, ZDV, and 3TC
compared to ten who received ZDV and 3TC. Approximately
half in each group had neuropsychological impairment and
this did not signiﬁcantly change at week 48. However, there
were several dropouts and the study was very signiﬁcantly
underpowered.
Given the above-mentioned points, it seems that there is
adequate theoretical reason to expect ABC to have neuro-
logical efﬁcacy. So perhaps this did not translate into practice
because of ﬂaws in trial design. In this regard, the ﬁrst
concern would be the presence of pre-existing resistance to
the drug. Certainly, at baseline, 90% of participants had virus
with evidence of resistance to the NRTIs and two thirds of
isolates had three or more NRTI-associated mutations at
baseline. The latter participants had less reduction in plasma
HIV-1 RNA compared to those with virus with two or fewer
mutations. As previously mentioned, recent data have shown
that the greater the number of NRTI mutations, the greater
the likelihood of ABC resistance [27]. Nonetheless, despite the
presence of multiple mutations, in this limited group of
patients signiﬁcantly more participants treated with ABC had
undetectable HIV-1 RNA at week 12 in the plasma and CSF.
So, while this was clearly a factor it is unlikely to be the most
important.
A second issue in trial design is that of the neurological
stability of the patient groups at entry. An 8-wk period prior
to entry was chosen because of pre-HAART data showing that
the vast majority of improvement had occurred by 8 wk from
commencement of a particular drug [4,31]. It was presumed
that even though some patients were on HAART, approx-
imately half in both groups at baseline, any improvement
would still have stabilized by 8 wk from commencement of
the regimen. At the time, this was based on the presumption
that HAART would not make a signiﬁcant impact on ADC
because of the limited penetration into the brain of the most
common component of such a regimen, namely the PIs. At
the time of the trial, HAART consisted of two NRTIs and a PI.
However, the fact that both the SBG and ABC groups
improved at week 12 of the study (that is, after at least 5 mo
on HAART) and that there were only two ADC progressions
(both in the SBG group) strongly suggest that HAART does
have efﬁcacy in ADC leading to a lengthening of the time
window. While there are no precise data on progression rates
prior to the introduction of HAART for the different ADC
stages, the mean time to death for Stage 2 ADC was 4.6 mo
and for all ADC patients the time was 6 mo [31,32]. These
ﬁgures therefore suggest that there should have been more
ADC progressions in the study participants if HAART had no
effect on dementia. The other interpretation, namely that the
neuropsychological improvement was related to a learning
effect for the tests seems unlikely: no similar improvement
has been observed in other clinical studies and further
analyses of the neuropsychological data comparing the results
of testing in the memory domain (the most sensitive to
learning effect) with the other tests of psychomotor function
and reaction time did not show any signiﬁcant differences.
Thus, unlike the issue of baseline resistance, this does seem to
be a major factor. In future ADC trials, patients should only
be entered after a period of 5 mo on existing HAART to
ensure stability.
A third issue in study design relates to whether or not the
trial was appropriately powered. The sample size calculation
was based on an estimated SD of 0.75, a difference between
treatment group responses of 0.60, and a dropout rate of
20%–25% giving the study a 90% power. These estimates had
been derived from previous MACS studies. However, the
observed SDs on the change in neuropsychological perfor-
mance from baseline were 1.27 (ABC þ SBG group) and 1.15
(SBG group). Because the variability of the neuropsycholog-
ical data was much greater than expected, the likelihood of
detecting any treatment differences was compromised. In-
deed the power of the study was reduced to 52%. With the
same sample size, but with the larger SD of 1.20, only
differences between treatment group responses on the order
of 0.96 would have been detected. Had the study been
planned with an SD of 1.20 (using all other assumptions)
rather than 0.75, approximately 115 patients per treatment
group (that is, approximately twice the number enrolled)
would have been required. It should be noted that two
HAART era studies conducted after the completion of this
study also showed unexpectedly large SDs of 1 and 1.5 [33,34].
It therefore seems that the MACS cohort data that were used
in the power analyses do not reﬂect ADC patients in the
HAART era. Indeed, future trial designs should utilize these
sample size re-estimations.
Lastly, and perhaps most importantly, the study was
designed to include participants with a diagnosis of ADC
not confounded by other illnesses, but there was no provision
to restrict entry to those who had ‘‘active’’ disease (that is,
ongoing brain damage). Some patients may have had
virologically or immunologically inactive disease while others
may have been in a ‘‘reparative’’ phase, perhaps analogous to
head injury or stroke patients who may take months to slowly
improve after the initial insult. Studies have shown a
correlation between ADC severity and CSF HIV-1 RNA and
b-2 microglobulin levels when used in pre-HAART era ADC
patients without other confounding conditions [31]. How-
ever, there are no consensus criteria by which ‘‘active’’ versus
‘‘burnt out’’ disease versus a ‘‘reparative’’ phase can be
differentiated. The fact that 56% of participants had a CSF
HIV-1 RNA level below 100 copies/mL at baseline strongly
suggests that many participants had a component of their
www.plosclinicaltrials.org March | 2007 | e13 0008
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neurological deﬁcit that was unlikely to be driven by ongoing
viral replication, and hence unlikely to be reversed by
antiretroviral agents. Moreover, the fact that 83% of
participants had CSF b-2 microglobulin concentrations that
were normal for an HIV-infected population also suggests
that most patients had a signiﬁcant component of their
deﬁcit that was not driven by immune activation or active
viral replication. How can this lack of virological and
immunological activity be reconciled with the fact that most
of the patients improved? We suggest that this may be related
to the patients being in a reparative phase of the illness:
possibly new synaptic connections are being made. It could
be hypothesized that CSF HIV-1 RNA .100 copies/mL and b-
2 microglobulin .3 nmoles/L should identify ‘‘active’’ ADC.
However, in a recent manuscript, we thoroughly explored this
with a negative result [35]. Elevation or non-elevation of any
one or combination of CSF markers at entry did not predict
stability, improvement, or worsening of ADC at week 12,
although there was a weak negative association with the
degree of elevation of CSF viral load at entry. Future studies
will need to focus on markers that can identify active ADC,
inactive or ‘‘burnt out’’ ADC, and address the possibility of
some patients entering a reparative phase. It is still possible
that CSF HIV viral load may be a good marker of activity if
the limit of detection can be reliably measured down to 10
cpml, for example. Thus, the issue of CSF markers will need
to be approached in two ways: the reﬁnement of existing
markers with greater sensitivity and the development of new
markers. Neuroimaging with spectroscopic analyses may also
be able to address the issue of ADC activity.
Moreover, this study highlights an important change in CSF
ADC markers in HAART-treated patients. No longer does the
CSF compartment as assessed by HIV RNA and immune
activation markers such as b-2 microglobulin reﬂect what is
occurring in the brain: there is no relationship to the severity
of ADC or to the risk of its worsening. This has been
conﬁrmed independently in another publication using a
different cohort of patients [36]. There are two explanations:
either the CSF compartment still reﬂects brain disease, but
current CSF markers are insensitive, or the CSF compartment
has become ‘‘separate’’ to the brain through HAART—
perhaps through differential activity in these compartments.
Future studies will need to address these possibilities.
Overall Evidence
This study highlights four issues that are critical in the
design of future ADC trials and in individual patient
management. Firstly, if a new antiretroviral agent is to be
trialed in ADC the details of resistance mutations to it should
be known before commencement of the trial so that patients
with resistant virus can be excluded from the trial. A
potential means of circumventing this problem in the case
of a novel agent where resistance patterns have not yet been
described (this was the case for ABC at the beginning of this
trial) would be to recruit only antiretroviral naı ¨ve patients.
However, this would mean that a large number of study sites
would have to be involved to enable the requisite number of
patients to be reached. Secondly, HAART has a beneﬁcial
effect on ADC which continues for at least 5 mo after
commencement of therapy. Thus, future ADC trials should
enroll patients after at least 5 mo of HAART. Thirdly, the
variability in neuropsychological performance over time is
greater than previously reported. These data should be used
to estimate the required sample size in future trials. Fourthly,
ADC patients should only be recruited into future anti-
retroviral trials if they have active virally mediated ADC. At
an individual patient level, it is not possible to be certain of
the degree of activity of ADC in a HAART-treated patient.
Consequently, clinicians are forced to consider an empirical
trial either of intensiﬁcation or change of HAART. Thus,
markers that allow ‘‘real time’’ evaluation of ADC activity, as
opposed to its retrospective identiﬁcation by history, are
urgently needed. In this regard, emerging data on the CSF
concentrations of the neuronal markers neuroﬁlament and
perhaps t-tau are promising [37–39].
While this trial delivered a negative result, it highlights
important factors that must be incorporated into a new design
methodology for future ADC trials in HAART-treated patients.
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